Molema G - Search Results

1

Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis.

Koning GA, Schiffelers RM, Wauben MH, Kok RJ, Mastrobattista E, Molema G, ten Hagen TL, Storm G. Koning GA, et al. Among authors: molema g. Arthritis Rheum. 2006 Apr;54(4):1198-208. doi: 10.1002/art.21719. Arthritis Rheum. 2006. PMID: 16575845 Free article.

2

Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate.

Everts M, Kok RJ, Asgeirsdóttir SA, Melgert BN, Moolenaar TJ, Koning GA, van Luyn MJ, Meijer DK, Molema G. Everts M, et al. Among authors: molema g. J Immunol. 2002 Jan 15;168(2):883-9. doi: 10.4049/jimmunol.168.2.883. J Immunol. 2002. PMID: 11777986

3

Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.

Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Asgeirsdóttir SA, Everts M, Meijer DK, Molema G. Kok RJ, et al. Among authors: molema g. Bioconjug Chem. 2002 Jan-Feb;13(1):128-35. doi: 10.1021/bc015561+. Bioconjug Chem. 2002. PMID: 11792188

4

Targeting of liposomes to angiogenic endothelial cells.

Schiffelers RM, Molema G, Ten Hagen TL, Janssen AP, Schraa AJ, Kok RJ, Koning GA, Storm G. Schiffelers RM, et al. Among authors: molema g. Cell Mol Biol Lett. 2002;7(2):255. Cell Mol Biol Lett. 2002. PMID: 12097939 No abstract available.

5

Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.

Schraa AJ, Kok RJ, Berendsen AD, Moorlag HE, Bos EJ, Meijer DK, de Leij LF, Molema G. Schraa AJ, et al. Among authors: molema g. J Control Release. 2002 Oct 4;83(2):241-51. doi: 10.1016/s0168-3659(02)00206-7. J Control Release. 2002. PMID: 12363450

6

Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.

Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G. Schraa AJ, et al. Among authors: molema g. Int J Cancer. 2002 Dec 10;102(5):469-75. doi: 10.1002/ijc.10727. Int J Cancer. 2002. PMID: 12432548

7

Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases.

Schraa AJ, Everts M, Kok RJ, Asgeirsdóttir SA, Meijer DK, de Leij LF, Molema G. Schraa AJ, et al. Among authors: molema g. Biotechnol Annu Rev. 2002;8:133-65. doi: 10.1016/s1387-2656(02)08007-9. Biotechnol Annu Rev. 2002. PMID: 12436918 Review.

8

Cellular handling of a dexamethasone-anti-E-selectin immunoconjugate by activated endothelial cells: comparison with free dexamethasone.

Kok RJ, Everts M, Asgeirsdóttir SA, Meijer DK, Molema G. Kok RJ, et al. Among authors: molema g. Pharm Res. 2002 Nov;19(11):1730-5. doi: 10.1023/a:1020769716288. Pharm Res. 2002. PMID: 12458680

9

Ligand-targeted liposomes directed against pathological vasculature.

Schiffelers RM, Molema G, ten Hagen TL, Janssen AP, Schraa AJ, Kok RJ, Koning GA, Storm G. Schiffelers RM, et al. Among authors: molema g. J Liposome Res. 2002 Feb-May;12(1-2):129-35. doi: 10.1081/lpr-120004785. J Liposome Res. 2002. PMID: 12604046

10

In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium.

Everts M, Koning GA, Kok RJ, Asgeirsdóttir SA, Vestweber D, Meijer DK, Storm G, Molema G. Everts M, et al. Among authors: molema g. Pharm Res. 2003 Jan;20(1):64-72. doi: 10.1023/a:1022298725165. Pharm Res. 2003. PMID: 12608538

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters